We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Pharmaceutical Sciences and Drug Design

2023 Volume 3
Creative Commons License

Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design


, , , ,
  1. School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, China.
  2. School of Science, China Pharmaceutical University, Nanjing 2111198, China.
  3. Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Abstract

Dolutegravir sodium is an effective antiretroviral medication used for the treatment of HIV. The drug is classified as BCS class II, indicating its low solubility at the typical gastric pH. The purpose of this research was to identify and optimize the key operational and formulation factors affecting the drug’s properties, using a 32-factorial design. Nanosuspensions were prepared using PVP K30, polyvinyl alcohol, polxammer 407, and polxammer 188. The study focused on polymer concentration as the formulation variable and homogenization speed as the manufacturing variable. Particle size and saturation solubility were the main parameters evaluated. The analysis of variance showed that both the polymer concentration and homogenization speed significantly affected the nanosuspension’s particle size and saturation solubility. The results, including contour plots and polynomial equations, provide useful insights into the optimization of the independent variables for the formulation of nanosuspensions with the desired properties.


How to cite this article
Vancouver
Xie B, Liu Y, Li X, Yang P, He W. Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design. Pharm Sci Drug Des. 2023;3:12-9. https://doi.org/10.51847/2uCOYf3jPn
APA
Xie, B., Liu, Y., Li, X., Yang, P., & He, W. (2023). Enhancing the Dissolution Rate of Dolutegravir Sodium Using Nanosuspension Technology and a 32 Factorial Design. Pharmaceutical Sciences and Drug Design, 3, 12-19. https://doi.org/10.51847/2uCOYf3jPn

About GalaxyPub

Find out more

Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.

Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.